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Introduction
Pentoxifylline (Trental®) (PTX) is a vasoactive drug, regis-
tered in 1972 to treat intermittent claudication in adults. More
recently, this drug has been of growing interest in different
conditions such as renal, vascular, inflammatory, and infec-
tious diseases. Particularly, it has been suggested that PTX
could be beneficial for sepsis in preterm neonates. A recent
Cochrane review including 6 relatively small studies showed
that PTX improves survival in neonatal sepsis [1]. How can
PTX, initially developed for a completely different population
and indication, save premature newborns with sepsis?
Repurposing of drugs
Using “old” drugs for new indications is called repurposing.
The development of new drugs (drug discovery) takes a lot of
time and resources [2], which makes drug repurposing attrac-
tive as an efficient way for “new therapies.”Drug repurposing
allows for shorter routes to the clinic and substantially lower
costs [3]. A well-known example of drug repurposing is sil-
denafil; sildenafil was repurposed from a hypertension drug to
a drug for erectile dysfunction, and subsequently for pulmo-
nary hypertension, also in neonates. Other illustrations specif-
ic to the field of neonatal pharmacotherapy are indomethacin,
ibuprofen, and paracetamol (pain and fever to patent ductus
arteriosus), propranolol (β-blocker to hemangioma), or
Insulin Growth Factor-1 (Laron dwarfism to retinopathy of
prematurity or bronchopulmonary dysplasia) [4].
Along this concept, PTXwas registered to treat intermittent
claudication and mainly used in the geriatric population when
Lauterbach et al. administered PTX off-label for the first time
in neonatal sepsis in 1994 [5]. From in vitro animal and adult
studies, it was observed that PTX could reduce tumor necrosis
factor alfa (TNF-a), and thereby could attenuate the hyper
inflammatory reaction. Lauterbach et al. hypothesized that
inhibiting TNF-a could enhance survival and administered
PTX to 16 septic neonates [6]. Since then, there has been a
growing interest in PTX for this particular indication [1].
Repurposing is a great opportunity, but still necessitates
product development for neonates. First, pharmaceutical for-
mulations for adults may need additional manipulations for
use in neonates. Second, formulations often contain excipients
that might be harmful or toxic to neonates, such as benzyl
alcohol and propylene glycol [7]. For example, the commer-
cially available preparation of doxapram (Dopram®) in the
USA is contraindicated for use in neonates as it contains ben-
zyl alcohol, which might be harmful to infants, while a benzyl
alcohol-free formulation in Europe enables a wider use to treat
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apnea of prematurity [8]. Third, data on compatibility of
repurposed drugs are needed. Due to the limited intravenous
accesses/catheters, simultaneous co-administration of drugs in
neonates is common. Incompatibility between drugs or excip-
ients may lead to lost efficacy of drugs or a physiochemical
precipitate that may damage blood vessels. Finally and most
relevant, a neonatal dosage cannot simply be extrapolated
from the adult dosage in the label, even more if the drug is
used for another indication. Unfortunately, for most drugs
used in neonates, the optimal dosage has not yet been inves-
tigated in phase II dose-seeking studies [9–11], as we com-
monly immediately jump to phase III research on efficacy in
neonates using a single dosage in the absence of prior dose-
finding study information. In the subsequent placebo con-
trolled trial, a sub-optimal dosage may be compared, leading
to sub-optimal findings or increased risk of adverse events.
Currently, this may also be the case for PTX. Several small
studies reported their attempt to assess the efficacy of PTX in
neonatal sepsis, and one study is ongoing; however, exposure-
effect responses are not yet studied.
Rationale of PTX therapy
In preterm neonates, an excessive inflammatory response to
infection can occur, characterized by high levels of pro-
inflammatory chemical biomarkers and associated with
multi-organ failure and mortality [12, 13]. Hence, it is thought
that anti-inflammatory agents, administered together with an-
tibiotics, may reduce mortality and morbidity in neonatal
sepsis.
In vitro and vivo studies documented that PTX has anti-
inflammatory effects: Toll-like receptor-mediated pro-
inflammatory cytokine production is inhibited [14] and pro-
duction of pro-inflammatory cytokines by phagocytes is re-
duced [15]. Additionally PTX improves microcirculation
[16], which is a key element in sepsis, and PTX may improve
hemodynamics in sepsis [17]. In 1996, Lauterbach et al.
showed that PTX modulates the excessive inflammatory re-
sponse in preterm neonates, which was characterized by a
reduction of the pro-inflammatory cytokine TNF-a, when
PTX was administered to preterm neonates with sepsis [5].
Also, during sepsis, the distribution of the antibiotics to the
infection site might be reduced by impaired microcirculation.
Considering that PTX improves microcirculation, it might fa-
cilitate distribution of antibiotics which may improve the effi-
cacy of antibiotic therapy.
PTX is metabolized to at least seven metabolites of which
three are considered to be pharmacologically active:
Lisofylline (M1), M4, and M5. M1 and PTX are found in
higher concentrations than M4 and M5 [18] and inhibit
TNF-a release more potently [19]. In adults, it is known that
hepatic impairment can influence the levels of PTX and its
metabolites [20]; hence, maturational changes are thought to
influence the exposure in preterm neonates. Recently, Salman
et al. reported a first population pharmacokinetic model of
PTX and its metabolites in a small cohort of 26 preterm infants
receiving one weight-based dosage, describing that clearance
of PTX increased with postmenstrual age [21].
PTX exposure-effect relation in preterm neonates:
data are needed
In adult patients, there is limited clinical benefit of PTX ther-
apy during sepsis.Moreover, in vitro, it has been observed that
the effect of PTX during hyper inflammation is less pro-
nounced in adult immune cells than in neonatal cells [22].
This highlights that neonates are not just small adults but a
vulnerable population with unique physiological characteris-
tics in whom we also should be aware of rapid maturational
changes in physiology [23], which may lead to altered re-
sponses to drugs.
It also emphasizes the importance of drug research in neo-
nates. Drugs developed and tested in adults and their subse-
quent dosages cannot just be extrapolated to neonates. Very
few dosing regimens used in neonates are based on research
within this specific population. Consequently, this population
of therapeutic orphans may receive sub-optimal treatment
[9–11]. Not giving the optimal dose is problematic: under-
dosing may result in inferior efficacy, over-dosing in adverse
drug reactions [24]. This may also be the case for PTX. In
1992, Lauterbach et al. [25] for the first time gave PTX to a
preterm neonate with a dose of 5 mg/kg/h during 6 h every
24 h for 3 days. However, this dosage was eminence-driven,
and not based on high-quality dose-finding research in pre-
term neonates. Thus, it is of great importance that the right
dosage for PTX is studied. Particularly in preterm neonatal
sepsis, lives could be saved by using the optimal dosage reg-
imen. Currently, we are conducting a dose optimization study
(phase II, exposure/response study) for PTX in preterm neo-
natal sepsis (Clinical Trials NCT04152980).
Current experience with PTX: is patient selection
and timing of PTX initiation relevant?
In this journal, Schüller et al. report their experience with PTX
in a retrospective cohort of 198 preterm neonates with either
severe sepsis or NEC. They used the dose 5 mg/kg/h for 6 h
daily (30 mg/kg/day), which is the dose that was used by
Lauterbach et al. and in other smaller studies [26]. As was
discussed earlier, compatibility might be a problem when
repurposing drugs. The results of Schüller et al. give insight
into the compatibility of PTX, and it is suggested that PTX is
compatible with other drugs commonly administered in neo-
nates. There were no serious side effects due to PTX. Their
findings suggest that PTX therapy is safe and well tolerated in
preterm neonates. Along the same research line, the
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PROTECT trial is recruiting 1800 preterm neonates to inves-
tigate PTX efficacy and safety (ACTRN12616000405415).
This will hopefully provide more conclusive results on the
efficacy of PTX in neonatal sepsis. However, there are poten-
tial drawbacks. Firstly, the dosage used (5 mg/kg/h for 12 h,
60 mg/kg/day for 2 up to 6 days) is neither thoroughly evalu-
ated with priori dose-finding data. Consequently, a sub-
optimal dosage may be studied. Secondly, any suspected pa-
tient will receive either placebo or PTX, while only 50% of the
included patients are expected to have a proven sepsis (or
NEC) within 48 h. This could result in overtreatment or signal
dilution and could be avoided by introducing objective bio-
markers (improve patient selection) that reflect disease sever-
ity and are associated with the subsequent clinical course. It is
reasonable to assume that PTX patients with (severe) sepsis
are most likely to benefit.
Besides case selection, timing also matters. In our center, we
use PTX since 2018 in preterm neonates with refractory septic
shock. In our experience, PTX might not be effective anymore
when the sepsis is already progressed to a stage of refractory
septic shock. This phenomenon was also observed in a porcine
septic model: when PTX was given when septic shock was
already established, PTX was not effective anymore and could
even have deleterious effects [27]. This emphasizes that the
timing of PTX therapy is of great importance; the sooner in
the inflammatory cascade PTX is started, the better.
In conclusion, PTX seems to be an effective and safe adju-
vant therapy to treat sepsis in preterm neonates as a potential
good illustration of repurposing to neonatal needs. Additional
research is needed to explore the exposure-response pattern of
PTX, as is the case for the majority of drugs used in neonates.
Furthermore, there is need for robust biomarkers to support
early patient selection and timing of PTX therapy. As PTX in
neonatal sepsis is a promising compound, these additional
drug repurposing efforts are important to really enable clini-
cians to give the right drug, in the right dose to the right
patient.
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